BioXcel Therapeutics (BTAI) Misses Q1 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil rises as Trump repeats Iran attack threat
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
BioXcel Therapeutics (BTAI) Reports Completion of Patient Enrollment in Phase 3 SERENITY Trials with BXCL501
May 14, 2020 7:09 AM EDTBioXcel Therapeutics, Inc. (NASDAQ: BTAI) today announced full enrollment of its pivotal Phase 3 SERENITY trials evaluating BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorder. The Company expects to report topline data from both trials in July of 2020.
Completing patient enrollment in our two Phase 3 studies marks a significant milestone for BTI, and lays the foundation for future growth as we look to pursue clinical trials for several additional indications for BXCL501, commented Vimal Mehta, Ph.D., Chief Executive Officer of BTAI. The BTI team has remained focused, with... More
